{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.77","value":"23.36"},{"groupId":"OG001","spread":"4.85","value":"23.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"566"}],"units":"Participants"}],"title":"Physical Well-being (PW), Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.54","value":"-0.91"},{"groupId":"OG001","spread":"4.59","value":"-0.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"511"},{"groupId":"OG001","value":"496"}],"units":"Participants"}],"title":"PW Change, Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.83","value":"-0.06"},{"groupId":"OG001","spread":"5.14","value":"0.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"482"},{"groupId":"OG001","value":"480"}],"units":"Participants"}],"title":"PW Change, End Induction"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.76","value":"0.83"},{"groupId":"OG001","spread":"5.09","value":"1.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"362"},{"groupId":"OG001","value":"398"}],"units":"Participants"}],"title":"PW Change, Maint Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.29","value":"1.14"},{"groupId":"OG001","spread":"4.74","value":"1.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"362"},{"groupId":"OG001","value":"406"}],"units":"Participants"}],"title":"PW Change, Maint Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.54","value":"0.88"},{"groupId":"OG001","spread":"5.00","value":"1.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"437"}],"units":"Participants"}],"title":"PW Change, End Maint"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.92","value":"22.84"},{"groupId":"OG001","spread":"4.77","value":"23.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"555"},{"groupId":"OG001","value":"563"}],"units":"Participants"}],"title":"Social/Family Well-being , Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.03","value":"-0.52"},{"groupId":"OG001","spread":"3.92","value":"-0.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"506"},{"groupId":"OG001","value":"492"}],"units":"Participants"}],"title":"S/FW Change, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.77","value":"-0.46"},{"groupId":"OG001","spread":"5.00","value":"-0.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"482"},{"groupId":"OG001","value":"475"}],"units":"Participants"}],"title":"S/FW Change, End Induction"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.72","value":"-0.39"},{"groupId":"OG001","spread":"4.68","value":"-0.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"396"}],"units":"Participants"}],"title":"S/FW Change, Maint Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.56","value":"-0.61"},{"groupId":"OG001","spread":"5.34","value":"-0.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"S/FW Change, Maint Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.67","value":"-0.93"},{"groupId":"OG001","spread":"5.54","value":"-0.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"436"}],"units":"Participants"}],"title":"S/FW Change, End Maint"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.19","value":"17.64"},{"groupId":"OG001","spread":"4.13","value":"17.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"563"}],"units":"Participants"}],"title":"Emotional Well-being (EW), Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.40","value":"1.49"},{"groupId":"OG001","spread":"3.35","value":"1.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"503"},{"groupId":"OG001","value":"490"}],"units":"Participants"}],"title":"EW Change, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.90","value":"1.16"},{"groupId":"OG001","spread":"3.87","value":"1.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"478"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"title":"EW Change, End Induction"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.88","value":"1.77"},{"groupId":"OG001","spread":"4.16","value":"1.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"396"}],"units":"Participants"}],"title":"EW Change, Maint Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.92","value":"1.45"},{"groupId":"OG001","spread":"3.88","value":"1.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"402"}],"units":"Participants"}],"title":"EW Change, Maint Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.98","value":"1.43"},{"groupId":"OG001","spread":"3.99","value":"1.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"435"}],"units":"Participants"}],"title":"EW Change, End Maint"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.19","value":"18.66"},{"groupId":"OG001","spread":"5.98","value":"18.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"563"}],"units":"Participants"}],"title":"Functional Well-being (FW), Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.30","value":"-0.30"},{"groupId":"OG001","spread":"5.24","value":"-0.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"488"}],"units":"Participants"}],"title":"FW Change, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.63","value":"0.44"},{"groupId":"OG001","spread":"5.85","value":"0.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"480"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"title":"FW Change, End Induction"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.31","value":"1.04"},{"groupId":"OG001","spread":"6.02","value":"1.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"396"}],"units":"Participants"}],"title":"FW Change, Maint Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.54","value":"1.84"},{"groupId":"OG001","spread":"5.95","value":"1.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"402"}],"units":"Participants"}],"title":"FW Change, Maint Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.12","value":"1.40"},{"groupId":"OG001","spread":"6.16","value":"1.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"436"}],"units":"Participants"}],"title":"FW Change, End Maint"}],"denoms":[{"counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"566"}],"units":"Participants"}],"description":"FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period was followed by either a maintenance or observation period for responders or non-responders, respectively. Responders received rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders received no protocol specified treatment during the 2-year observation period. Finally, participants were followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"OG000","title":"Rituximab+Chemotherapy"},{"description":"Participants received either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period was followed by either a maintenance or observation period for responders or non-responders, respectively. Responders received obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders received no protocol specified treatment during the 2-year observation period. Finally, participants were followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"OG001","title":"Obinutuzumab+Chemotherapy"}],"paramType":"MEAN","populationDescription":"The FL ITT population was defined as all randomized participants with follicular histology grouped according to their randomized treatment arm regardless of what treatments were actually received.","reportingStatus":"POSTED","timeFrame":"Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)","title":"Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)","type":"SECONDARY","unitOfMeasure":"units on a scale"}